Status:
COMPLETED
Pemetrexed in Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Armando Santoro, MD
Conditions:
Non-small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Brief Summary
Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor tissue available at our institution
- Patients treated with single agent pemetrexed for metastatic disease
- Availability of full clinical data
Exclusion
- Cytological diagnosis of advanced Non-small cell lung cancer
- Lack of tumor tissue at our institution
- Lack of full clinical data
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01193959
Start Date
September 1 2010
End Date
June 1 2012
Last Update
September 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089